anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Lung cancer stands as the most prevalent form of cancer globally, posing a significant threat to human well-being. Due to the lack of effective and accurate early diagnostic methods, many patients are diagnosed with advanced lung cancer. Although surgical resection is still a potential means of eradicating lung cancer, patients with advanced lung cancer usually miss the best chance for surgical treatment, and even after surgical resection patients may still experience tumor recurrence. Additionally, chemotherapy, the mainstay of treatment for patients with advanced lung cancer, has the potential to be chemo-resistant, resulting in poor clinical outcomes. The emergence of liquid biopsies has garnered considerable attention owing to their noninvasive nature and the ability for continuous sampling. Technological advancements have propelled circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), extracellular vesicles (EVs), tumor metabolites, tumor-educated platelets (TEPs), and tumor-associated antigens (TAA) to the forefront as key liquid biopsy biomarkers, demonstrating intriguing and encouraging results for early diagnosis and prognostic evaluation of lung cancer. This review provides an overview of molecular biomarkers and assays utilized in liquid biopsies for lung cancer, encompassing CTCs, ctDNA, non-coding RNA (ncRNA), EVs, tumor metabolites, TAAs and TEPs. Furthermore, we expound on the practical applications of liquid biopsies, including early diagnosis, treatment response monitoring, prognostic evaluation, and recurrence monitoring in the context of lung cancer.
This will be a multi-site study adopting a prospective, observational cohort study design. There will be no intervention to the standard of care. Study participants will be enrolled in this study for a total of 5 years, with only 1 month of active participation. Participants will be required to attend a screening visit and 2 study visits. The screening visit will involve a medical review and receiving informed consent based on the participant information leaflet already communicated to the patient, pre-screening. The first study visit- baseline (visit 1) - will involve anthropometric measurements and taking a blood and urine sample in order to perform standard of care measurements for type 2 diabetes at baseline and relevant circulating biomarkers. The second study visit will involve having a multi-organ, multiparametric MRI scan. Both visits will be within 28 days of the screening visit and carried out at local study sites.

MRI metrics of organ health, clinical outcome measurements, blood samples and urine samples will be collected to assess the natural history of diabetes disease progression. Participants will be asked to give consent for access to their medical records held at NHS England and, if available, at their local GP surgery or hospital. Medical records access will include Hospital admissions (Hospital Episode Statistics), and mortality data collected by the Office for National Statistics and provided by NHS England to meet the primary objective. This data will be collected at 1, 3 and 5 years after baseline assessment.
Methods and compositions for treating Gaucher disease are described. Methods and compositions for treating Gaucher disease are described. A system for characterizing crude oil fractions includes a maltenes sample reservoir, a first solvent reservoir, a second solvent reservoir, and a third solvent reservoir. The system further includes a valve in fluid communication with the first solvent reservoir, the second solvent reservoir, and the third solvent reservoir and a pump in fluid communication with the valve. The system further includes a packed bed in fluid communication with the maltenes sample reservoir and the pump, a flowthrough cell in fluid communication with the packed bed, a spectrometer operably associated with the flowthrough cell, and a computer operably associated with the spectrometer. A method for characterizing crude oil fractions includes providing a maltene sample, eluting saturates, aromatics, and resins of the maltene sample, determining an optical density of each, and determining a concentration of each of the saturates, aromatics, and resins based upon optical densities over time for each.
A quick-change tool holder includes a center-height adjustment mechanism for adjusting the center height of the cutting tool. The quick-change tool holder includes a tool support member which is adapted to be mounted on a lathe turret or mounting block of a machine, a cutting head formed with a seat for receiving a cutting tool, and a clamping mechanism for clamping the cutting head to the support member. The tool support member includes an axial bore which receives a tubular shank of the cutting unit. The clamping mechanism is disposed within the axial bore and includes a pair of radially expandable locking elements to engage the tubular shank of the cutting unit. The clamping mechanism includes a key which engages with a corresponding keyway on the tubular shank for angularly locating the cutting unit. An adjustment mechanism is provided for rotating the clamping means about a longitudinal axis of the support member to change the angular location of the cutting unit. The center height of the cutting tool is determined by the angular location of the cutting unit.
Returning veterans from Iraq and Afghanistan (OIF/OEF veterans) have a very high incidence of TBI (14-23%) with the largest number having mild TBI (i.e., no discernible structural brain damage) with 63.5% having persistent headache. Treatment of PTH in this population has been difficult and mind/body interventions including Mindfulness Based Stress Reduction (MBSR) may offer significant benefit. A biomarker that will support clinical endpoints ("surrogate endpoint") and help predict clinical benefit, could be used to more efficiently and completely assess mind/body treatment effects in clinical trials for PTH, compare various complementary and alternative medicine (CAM) treatments, and potentially target specific treatments to patients most likely to benefit. This project aims to investigate candidate biomarkers for MBSR response in veterans with PTH. Primarily, all subjects if they are interested and appropriate for the study, will undergo a screening at their regular clinic visit at the VAGLAS physical medicine and rehab department. If a subject responds to advertisement they will be screened using the same tools and enrollment criteria required for the veterans at VAGLAS. We expect we will need to enroll and screen no less than 33 subjects in order to complete 20 evaluable subjects for analysis. The study subjects will be evaluated for the severity of their PTH, the impact of PTH on their life, and the extent of the disease/pain condition. If eligible the nurse coordinator will contact them to schedule the pre-MBSR functional MRI visit. At the MRI we will evaluate patterns of activity (functional connectivity) in the brain at rest, and look at cortical thickness. Following the MRI visit all subjects will complete a 9-week modified MBSR training with a qualified instructor. Mid-study (after MBSR class 4) the subject will be asked to complete mid-study questionnaires at home on Survey Monkey or on paper if they choose. At the end of the MBSR training in which the subject will have to complete at least 3 visits, functional (f)MRI procedure will be repeated and compared against the first. Three months after completing the study there will be a follow-up visit to complete behavioral/symptom/quality of life questionnaires on line via SurveyMonkey. This is to see if the changes in the biomarkers will mediate changes in these behavioral measures 3-mo post Treatment (i.e. measure stability).

All in all, to complete the study subjects will have a screening visit, pre and post training MRI visit, up to 9 MBSR training visits, mid study questionnaires, a 4-hr retreat visit after week 6 and a final 3-mo f/u visit for questionnaires only.
Patients will receive 2 courses of standard ABVD (ABVD-28, d1, d15, cycles of 28 days) and then proceed to interim PET/CT evaluation. Those with a PET-2-negative scan (score 1-3 on 5PS) will continue with additional 4 ABVD courses while those with a PET-2-positive (score 4-5) scan will be diverted towards an intensification phase with either escalated BEACOPP or HDT plus ASCR, according to the preference of the centre. Upon completion of treatment, patients will be categorized for response (Lugano2014) by comparing actual PET/CT imaging with baseline, whether 6 ABVD cycles or ABVDx2 + intensification phase with BEACOPP or HDT/ASCR. A salvage rescue program will be planned for patients with Stable (\<PR) or Progressive Disease. ISRT 30 Gy will be delivered to complete responders (5PS score 1-2-3) on the initial bulky site(s), to focal rests in case of CR scoring 3 on 5PS with a residual size ≥ 2.5 cm and to focal rests uptakes in the event of PR scoring 4 or 5, whichever is the size.
Promethazine Hydrochloride and Phenylephrine Hydrochloride Syrup is a yellow-orange colored, fruit flavored syrup. Each 5 mL (one teaspoonful), for oral administration contains: Promethazine hydrochloride 6.25 mg; phenylephrine hydrochloride 5 mg. Alcohol 7%. 

Inactive Ingredients: Sucrose syrup, sodium benzoate, sodium citrate, propylene glycol, citric acid, ascorbic acid, methylparaben, propylparaben, FD&C Yellow No. 6, natural tangerine extract and purified water.

Promethazine hydrochloride, a phenothiazine derivative, is chemically designated as (±)-10-[2-(Dimethylamino)propyl] phenothiazine monohydrochloride.

Promethazine hydrochloride occurs as a white to faint yellow, practically odorless, crystalline powder which slowly oxidizes and turns blue on prolonged exposure to air. It is soluble in water and freely soluble in alcohol. It has a molecular weight of 320.88, a molecular formula of C17H20N2S • HCl, and the following structural formula:

Phenylephrine hydrochloride is a sympathomimetic amine salt which is chemically designated as (-)-m-Hydroxy-α-[(methyl amino)methyl]benzyl alcohol hydrochloride. It occurs as white or nearly white crystals, having a bitter taste. It is freely soluble in water and alcohol. Phenylephrine hydrochloride is subject to oxidation and must be protected from light and air. It has a molecular weight of 203.67, a molecular formula of C9H13NO2 • HCl, and the following structural formula:
Contact lens (CL) wearers frequently face eye discomfort symptoms, especially towards the end of the wear day. This burdensome discomfort can unfortunately cause patients to remove their CLs before their desired wear time. While comfortable wear times vary from patient to patient, Terry et al. has suggested that patients should be able to comfortably wear their CLs for at least 12 hours per day for at least 6 days per week. Nevertheless, the literature currently lacks sufficient data to comment fully on the full day wear experience, which for many patients may be 16 or more hours per day, especially if they have demanding careers. One CL that has the potential to allow for all day comfort is the Total30 Sphere CLs, which is a new water gradient, monthly CL aimed at delivering all day comfort and visual performance. Thus, the purpose of this study is to map comfort over the full wear day in established, asymptomatic, soft CL wearers who are refit in Total30 Sphere CLs. These data are not only important for judging the performance of Total30 Sphere CLs, but they will provide some of the first insights into the full day CL wearing experience over one month.
In Step 1, participants will receive ARV therapy for 24 weeks. Upon entering Step 2, participants will stop ARVs for 4 weeks, take ARVs for 8 weeks, stop ARVs for 4 weeks, take ARVs for 8 weeks, and then stop ARVs for 56 weeks.
1355828 Coating apparatus TAKEDA YAKUHIN KOGYO KK 29 Dec 1971 [29 Dec 1970] 60426/71 Heading B2L Apparatus for coating particulate material such as tablets comprises a coating chamber 11 having a cylindrical drum 11 a and a rotatable plate 12a with means 31a to detect the amount of coating liquid in the mixture. Granules to be coated are placed in the chamber by means of a hopper 21 and a powder to be coated on the surface thereof is introduced through a hopper 22. A liquid to help with the distribution of the coating powder is introduced through a tube 23b by an air stream or as an airless spray. The amount of liquid introduced is controlled by a valve 23a dependant on the specific resistance of the mixture as measured between an electrode 31a and the side of the coating chamber. Air is introduced by a blower 24 below the rotating plate, which has a central frustrum 12b, and may be drawn out by an extractor 14. Air passing around the edge of the plate 12a prevents powder falling below the plate. Hot air may be introduced through a pipe 25 to dry the coated granules and the extractor 14 collects excess dry powder. A thermometer 32a is also placed in the coating drum. The drum may be used for batch coating or for a continuous coating process.
Number of participants in this group is anticipated to be 20. Conventional physiotherapy and rehabilitation methods will be applied to this group. The conventional program includes the application of Transcutaneous Electrical Nerve Stimulation (TENS), cold pack, therapeutic ultrasound, Codman Exercises, Wand exercises, shoulder wheel exercises, finger ladder exercises, strengthening exercises with elastic band and capsule stretching.
The invention relates to the technical field of medicines, in particular to application of LY3009120 in preparing a medicine for treating myeloproliferative tumors. Myeloproliferative tumors include polycythemia vera, essential thrombocythemia and myelofibrosis, especially may be drug resistant. LY3009120 is used for the treatment of myeloproliferative tumor and provides a new treatment approach for patients with myeloproliferative tumor, and provides more choices for clinicians and patients. LY3009120 provides continued oral drug therapy for patients with reed catinib resistant myeloproliferative tumors, free of receiving bone marrow transplantation. LY3009120 can be chemically synthesized at a lower cost than biological agents. And has already passed the first clinical trial, its side effect is less light, and clinical patient's tolerance is good.
Huangqi Guizhi Wuwu Decoction (HQGZWWD) has shown promising potential in treating various cardiovascular diseases. This study aimed to elucidate the molecular basis and therapeutic role of HQGZWWD in the treatment of doxorubicin (DOX)-induced myocardial injury. The HPLC fingerprint of HQGZWWD was used to analyze the active components. A DOX-induced myocardial damage rat model was developed, and the therapeutic effects of HQGZWWD were evaluated using echocardiography, myocardial enzyme levels, and hematoxylin and eosin staining. Network pharmacology was used to screen treatment targets, and western blotting and immunohistochemistry were performed to assess cellular pyroptosis levels. Oxidative stress levels were measured using assay kits, and mitochondrial damage was examined using transmission electron microscopy. An in vitro model of DOX-induced cell damage was established, and treatment was administered using serum containing HQGZWWD and N-acetylcysteine (NAC). Oxidative stress levels were detected using assay kits and DCFH-DA, whereas cellular pyroptosis levels were assessed through WB, immunofluorescence, and ELISA assays. HQGZWWD ameliorated DOX-induced myocardial injury. Network pharmacology identified IL-1β and IL-18 as crucial targets. HQGZWWD downregulated the protein levels of the inflammatory factors IL-1β and IL-18, inhibited the expression of GSDMD-NT, and simultaneously suppressed the synthesis of Caspase-1, ASC, NLRP3, and Caspase-11. Additionally, HQGZWWD inhibited oxidative stress, and the use of NAC as an oxidative stress inhibitor resulted in significant inhibition of the GSDMD-NT protein in H9C2 cells. These findings highlight the myocardial protective effects of HQGZWWD by inhibiting oxidative stress and suppressing both canonical and non-canonical pyroptotic pathways.
FIELD: veterinary. SUBSTANCE: preparation contains (mass %): dioxidine 0.90-1.05, gelatin 12.88-17.20, glycerin 49.55-51.39 and distilled water the rest. Said preparation is used for treatment and prophylaxis of uterus inflammation at cows after pathologic or complicated labor, namely, acute puerperal endometritis, catarrhal and purulent-catarrhal endometritis, uterine prolapse, cesarean section and metritis. Preparation is applied intrauterinely as stick per 3-5 sticks in 8-12 h intervals till neck of uterus is not closed. Said preparation is applied once for prophylaxis. EFFECT: improves efficiency of preparation.
Provided herein are peptide amphiphiles (PAs). In some embodiments, provided herein are PEGylated PAs (e.g. nonionic PAs). In some embodiments, the peptide amphiphiles are assembled into nanofibers. The nanofibers may further comprise a growth factor protein, which may bind to a growth factor binding sequence presented on the nonionic PA. In some embodiments, the nanofibers further comprise a charged peptide amphiphile. The charged peptide amphiphile may be bound to a growth factor protein. Further provided herein are methods of use of the peptide amphiphiles and compositions comprising the same, such as for regenerative therapy.
This is a phase 2 clinical study in humans for therapeutic use of Capsicum oleoresin - (capsaicin) in CIC. The study has a randomised, double-blind and cross-over design. During 4 weeks the participants take either active capsules (Capsicum oleoresin), or matching placebo capsules. This period follows by 2 weeks of "wash out" and then another 4 weeks with active capsules or placebo in accordance with the trial profile below.
This project develops and evaluates an online learning environment of web-based intervention modules designed to promote family and child coping and adjustment (GROW: Gaining Real-life Skills Over the Web) based on a comprehensive needs assessment of children aged 0 to 14 years old, who experienced a traumatic brain injury (TBI) between the ages of 0 to 4 years, and their families. The incidence of TBI peaks between the ages 0 to 4 years, yet there are no evidenced-based interventions to facilitate neurocognitive development and socio-emotional functioning of children injured during this critical development period. To address the unmet need of caregivers of infants and toddlers with TBI, the project uses a three-phase development process to generate proof of concept and initial proof of product. Phase 1 involves a comprehensive needs assessment that includes quantitative assessment of family and child needs, qualitative assessment through focus groups and interviews of families, feedback from family and professional advisory boards, and consultation with professionals implementing interventions with similar populations (e.g., families of children with very low birth weight). During Phase 2, the project develops the content and manual for the intervention modules, designs the online learning environment, and conducts intensive, iterative usability testing. Phase 3 involves a pilot of the GROW program with 20 families to evaluate its usability, acceptability, and qualitative and quantitative impact on stakeholder identified outcomes.
<P>PROBLEM TO BE SOLVED: To provide a liver fat accumulation inhibitory agent derived from colored rice and useful for the prevention and treatment of lifestyle-related diseases such as hyperlipidemia, fatty liver, diabetes, etc., and a medicine and skin preparation for external use (cosmetic).  <P>SOLUTION: This liver fat accumulation inhibitory agent comprises a pigment extract of the colored rice as effective components. The pigment extract is preferably a defatted rice bran extract of the colored rice. The liver fat accumulation inhibitory agent is characterized in that the colored rice is black rice or red rice. The beverages, foods, medicines and skin preparations for external use (cosmetics) comprise the above liver fat accumulation inhibitory agent. Further, as to the liver fat accumulation inhibition, in the fat metabolism passway shown in drawing, it is associated with (4) fat combustion acceleration, and not directly associated with effects caused by (1) fat absorption inhibition to (3) fat decomposition acceleration.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Provider Training: i. on-line education course and ii. algorithms and checklists. The course consists of 4 cases: 2 for urinary tract infection and 2 for lower respiratory tract infections with multiple choice questions and evidence-based feedback. To reinforce provider learning, posters displaying algorithms guiding appropriate antimicrobial initiation for infections will be placed in all nursing home units. Laminated pocket cards with the algorithms will be given to providers. Providers will complete simple checklists for each suspected infection throughout the study. B. Proxy Information: The printed material explains, in a lay fashion: i. the nature of infection in advanced dementia, ii. treatment options, iii. concerns about antimicrobial overuse, and iv. features of appropriate antimicrobial use.
Method of hollow micro-projections having side walls and at least one opening in a side wall, by a molding technique. The hollow micro-projections are defined by a first, negative mold defining the exterior shape of the micro-projections and a second, positive mold defining the hollow interior shape of the micro-projections. The method includes injecting a moldable material into the space between the two molds, in a state where they have been brought together. The positive and negative molds each have an essentially cylindrical geometry. In the process of bringing the molds together, the mold halves are laterally off-set with respect to each other, such that the distance between an inner wall of the negative mold and the positive mold in the area, ranges from zero to a finite distance. Micro-projections and arrays of micro-projections are also disclosed.
The invention provides a triptolide derivative, and a preparation method and application thereof, and belongs to the technical field of medicinal chemistry. The triptolide derivative provided by the invention has a structure shown in a formula (I). Pharmacological activity experiments show that the triptolide derivative and the pharmaceutically acceptable salt or precursor thereof provided by the invention have good inhibitory activity on HIV-1 protease, and can be used as an active ingredient of an anti-AIDS drug. The invention provides a preparation method of the triptolide derivative, which is simple to operate and easy to realize industrialized mass production. Furthermore, the invention provides an anti-AIDS pharmaceutical composition, which comprises an active ingredient and a pharmaceutical carrier, wherein the active ingredient is the triptolide derivative and pharmaceutically acceptable salts or precursors thereof. The pharmaceutical composition is useful as an HIV-1 protease inhibitor.
Superoxide dismutase derivs. of formula (SOD)(Z)x(I) are prepd., where SOD is superoxide dimutase residue with C1-6 amino acid residues, Z is monovalent copolymer residue having an average mol. wt. of 800-20,000. (I) are useful for treatment of inflammations, ischaemic disorders, cerebral edema or paraguat poisoning. Also (I) can suppress adverse effects due to active oxygen radicals of antitumour agents.